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ABSTRACT 
The following study examined the acute hormonal response to androstenedione 
ingestion in eight college-aged females. Between days three and five of the follicular phase 
and between 6am and 9am, subjects ingested placebo (100 mg rice pill), 100, or 300 mg of 
androstenedione in a random, double-blind, cross-over manner. Blood samples were 
collected before and every 30 min for 240 min post ingestion. Androstenedione ingestion 
increased serum androstenedione concentrations (basal 6.2 ± 0.8 nmol/L) at each time point 
from 60 to 240 min for both 100 mg (peak at 240 min = 22.6 ± 1.0 nmol/L) and 300 mg 
(peak at 210 min= 28.1 ± 1.3 nmol/L). Ingestion of 300 mg resulted in higher 
androstenedione concentrations at each time point from 120 to 240 min. Ingestion of 
androstenedione increased serum estradiol concentrations (basal 191 ± 24 pmol/L) only at 
150 min with 100 mg (237 ± 35 pmol/L) and at each time point from 150 to 240 min with 
300 mg (peak at 240 min = 260 ± 32 pmol/L). Androstenedione ingestion increased serum 
total testosterone concentrations (basal 1.2 ± 0.2 nmol/L) at each time point from 120 to 240 
min (peak at 210 min = 5.5 ± 0.9 nmol/L) with 100 mg and from 60 to 240 min with 300 mg 
(peak at 210 min= 10.2 ± 1.6 nmol/L). Ingestion of 300 mg androstenedione caused a larger 
increase than the 100 mg at each time point from 120 to 240 min. These data suggest that 
androstenedione ingestion by young females results in significant increases in serum total 
testosterone concentration and other significant changes in the hormonal profile. 
CHAPTERl 
INTRODUCTION 
Testosterone enhances the development of muscle and strength. There are currently 
several nutritional supplements on the market advertised to either "increase the natural 
release" of testosterone, or "enhance its metabolic effects." Although oral supplementation 
of androstenedione has been suggested to increase blood testosterone concentrations, the 
conversion of androstenedione to testosterone in both males and females is a complex 
process and not well understood. 
Both pre- and post-menopausal females may be on androgen therapy for increasing 
testosterone levels and thus the alleviation of androgen deficiency symptoms such as 
premature ovarian failure and post-menopausal and glucocorticosteroid-related bone loss 
(12). However, there is not valid research which closely examines the hormonal response to 
oral androstenedione ingestion in females. In addition, amateur and professional female 
athletes and competitors often are looking for a legal ergogenic aid to possibly improve their 
performance by the slightest edge. Discovering a supplement, such as androstenedione, 
which increases testosterone concentration with supplementation may be a beneficial 
ergogenic aid for such athletes and competitors. 
Dehydroepiandrosterone (DHEA) and its sulfate ester (DHEA-s) are androgenic 
hormones produced primarily by the adrenal glands, which serve as immediate precursors to 
androstenedione (30). In the adrenal cortex, blood-borne DHEA can be converted to 
androstenedione, which later can be dehydrogenated in the liver to testosterone (30). 
1 
Dehydroepiandrosterone supplementation has been shown to increase testosterone 
concentrations in women (36,37 ,38,46). 
2 
Androstenedione is an immediate precursor to the formation of testosterone through 
the action of the 17 ~-hydroxysteroid dehydrogenase enzyme. Androstenedione can also be 
aromatized to estrone through the action of the aromatase enzyme. However, the 
biosynthesis of testosterone from androstenedione and other androgens differs between the 
genders, which makes increasing testosterone levels from oral androstenedione 
supplementation in women unclear. In men, research has shown that a single ingestion of 
<300 mg androstenedione does not increase serum testosterone concentrations 
(3,8,25,27,41,49). However, in women approximately 60% of plasma testosterone is derived 
from plasma androstenedione, while only 2% of plasma testosterone results from plasma 
androstenedione in men (22). Since testosterone formation from androstenedione is greater 
in women and oral androstenedione has been shown to increase serum androstenedione 
concentrations in women (36,37,38,46), women may show increases in serum testosterone 
with androstenedione supplementation. Only one study has looked at the acute effects of 
androstenedione supplementation on serum testosterone concentrations in women (32). A 
100-mg dose of androstenedione was ingested in this study, which resulted in significant 
increases of serum testosterone in two female subjects. 
Since serum androstenedione is a quantitatively more important precursor to 
testosterone in females, we hypothesize that oral supplementation of androstenedione will 
increase serum testosterone concentration levels in women. Therefore, the purpose of this 
study is to examine the acute effects of 100- and 300-mg oral androstenedione on serum 
testosterone concentration and other sex steroid hormone concentrations. 
CHAPTER2 
REVIEW OF LITERATURE 
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The use of supplements to increase testosterone and therefore enhance muscle growth 
raises skepticism in sports and society. Research suggests that oral administration of 
androstenedione of <300 mg does not increase testosterone in males (3,8,25,27,41,49), while 
a 300-mg dose produces a small and transient effect (27). The acute hormonal effects of 
orally administered androstenedione have been far less studied in females, with only one 
previous study conducted. The following review of literature will examine: (a) the enzyme 
kinetics of two major enzymes in the conversion of androstenedione to testosterone and 
estrogens; (b) ovarian steroidogenesis; ( c) ovarian hormones; ( d) androstenedione research in 
males; (e) androstenedione research in females; and (f) possible reasons for different 
hormonal responses to androstenedione between genders. 
Enzyme Kinetics 
It has been observed previously in young men that ingestion of androstenedione 
caused a significant increase in serum estradiol (8,25,27,41). In men, the enzyme kinetics for 
the aromatization of androstenedione to estrone (Km=25 nmol·L-1) (37) catalyzed by P450 
aromatase favor the production of estrogens when compared to the 17(3-hydroxysteroid 
dehydrogenase conversion of androstenedione to testosterone (Km=l,500 nmol·L-1) (37). 
Thus, the differences in the Michaelis constant between the two major enzymes involved in 
testosterone and estrogen conversion support the findings of enhanced serum estradiol 
concentrations with androstenedione ingestion in men. In women, the Michaelis constant of 
both P450 aromatase and 17'3-hydroxysteroid dehydrogenase in the conversion of 
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androstenedione to estrone and testosterone, respectively, are currently unknown. However, 
it is thought that the difference between the two Michaelis constants is less in females and 
thus possibly tends to convert more androstenedione to testosterone compared to males. 
Strict enzymatic regulation of testosterone ultimately derives from the conversion of both 4-
androstene-3,l 7dione (=4) and 5-androstene-3 f3,17f3-diol (::5diol) (45), while =4 oral (32) 
and percutaneous (15) supplementation has readily observed increases in in vivo testosterone 
concentrations in females. Therefore, hypotestosteronic individuals such as females appear 
to favor the conversion of androstenedione to testosterone through the enzymatic activity of 
17 f3-hydroxysteroid dehydrogenase and therefore less aromatization of androstenedione to 
estrogens as compared to males. 
Ovarian Steroidogenesis 
The ovarian steroids include estrogens (estradiol, estriol, estrone), progestins 
(progesterone, 17 f3-hydroxyprogesterone ), and androgens ( dehydroepiandrosterone, 
androstenedione, testosterone). These ovarian steroids are produced by thecal and granulosa 
cells. The main steroids produced by the ovary are progesterone and estradiol (see Fig. 1). 
Although some androgens, particularly androstenedione and testosterone, are secreted into 
the bloodstream, a significant portion of androgens are converted to estradiol through the 
action of the aromatase enzyme complex in the ovary and therefore never released into the 
bloodstream as androstenedione or tesosterone. In addition to androstenedione and 
testosterone, the ovary also secretes estrone, 17 a-hydroxyprogesterone, 20 a-
hydroxyprogesterone, and 5 a-reduced androgens such as 5 a-dihydrotestosterone and 3 a-
androstenediol. 
I Cholesterol 1-1-.1 Pregnenolone 1~1 Progesterone 
l 3 l 3 
17a-Hydroxy 17a-Hydroxy 
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t 4 t 4 
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Testosterone 1~1 Estradiol 
Figure 1. Biosynthesis of steroids in the ovary. 1, Cholesterol side-chain cleavage enzyme 
complex; 2, 3 ~-hydroxysteroid dehydrogenase; 3, 17 a-hydroxylase; 4, 17,20-lyase; 5, 
aromatase; 6, 17 ~-hydroxysteroid dehydrogenase 
Steroid Biosynthesis 
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The initial precursor for steroid biosynthesis is cholesterol (see Fig. 1), which comes 
from the plasma low-density lipoprotein (LDL)-associated pool, intracellular lipid droplets, 
and through de novo local synthesis (16). Cholesterol, which has 27 carbons, is converted to 
the 21 carbon compound pregnenolone in a reaction catalyzed by an enzyme complex known 
as cholesterol side-chain cleavage enzyme. The reaction occurs in the mitochondria and is a 
rate-limiting step in the steroid biosynthetic pathway. Pregnenolone is converted into 
progesterone by the action of a 3 ~-hydroxysteroid dehydrogenase enzyme, or converted into 
17 a-hydroxypregnenolone by a 17 a-hydroxylase. Progesterone and 17 a-
hydroxypregnenolone can b~th be metabolized to 17 a-hydroxyprogesterone. 
Further metabolism to androgens and estrogens results in further reduction in the 
number of carbons to 19 (androgens) and 18 (estrogens). 17 a-hydroxyprogesterone is the 
substrate for a 17,20-lyase enzyme that forms androstenedione (5,16,33). Androstenedione 
can also be synthesized from DHEA, a substrate for the enzyme 3 f3-hydroxysteroid 
dehydrogenase. Androstenedione is either metabolized to estrone through the enzyme 
aromatase or converted into testosterone in a reaction catalyzed by the enzyme 17 f3-
hydroxysteroid dehydrogenase. Testosterone, like androstenedione, can also be metabolized 
into estradiol by the P450 aromatase enzyme (16,33). The biosynthesis of these ovarian 
steroids (estrogen, progesterone, androgen) occurs in interstitial granulosa cells and the cells 
of the follicular theca, where production is controlled by two main hormones, luteinizing 
hormone (LH) and follicle-stimulating hormone (FSH) (16). 
Control of Ovarian Steroid Production through LH and FSH 
Ovarian steroids are produced under the control of LH and FSH. Only LH enhances 
the secretion of androgens. However, both LH and FSH stimulate the secretion of 
progesterone. The formation of estradiol also depends on both FSH and LH. Estrogen 
production, from androgens, is stimulated by LH, while the aromatase enzyme complex that 
catalyzes the conversion of androgens to estrogens is directly activated by FSH (see Fig. 2). 
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Figure 2. The control of ovarian estrogen, progesterone, and androgen production by LH 
and FSH. Cholesterol side-chain cleavage enzyme complex (SCC); 3 (3-hydroxysteroid 
dehydrogenase (3(3-HSD); Luteinizing hormone (LH); Follicle-stimulating hormone (FSH). 
Thecal and Granulosa Cells - The "Two-Cell" Hypothesis 
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The predominant site of androgen synthesis in the preovulatory follicle is the theca 
intema (thecal cell). Thecal cells can be compared to the Leydig cells of the testis in males. 
Although the thecal cells can produce estrogen, the predominant hormones are the androgens 
DHEA and androstenedione. Granulosa cells are the predominant site of estradiol production 
in the preovulatory follicle, and can be compared to the testicular Sertoli cells. Since thecal 
cells provide the precursors for granulosa cell estrogen production, both cell types are 
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Figure 3. Two-cell theory of early follicular steroidogenesis. Luteinizing hormone (LH) 
stimulates thecal steroidogenesis; primary product is androgen. Follicle-stimulating hormone 
(FSH) stimulates granulosa cell aromatization of thecal androgens to produce estrogen. 
neccessary for optimal estrogen production (23) (see Fig. 3). 
Both thecal cells and granulosa cells, which produce progesterone and androgens, 
have LH receptors. The cells' exposure to LH results primarily in increased production of 
progesterone and a small production of androgens due to their limited 17 ,20-lyase activity 
(23). However, only granulosa cells have FSH receptors, which are the only ovarian cells 
with high aromatase activity. 
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Conclusion 
The synthesis of ovarian steroids is a complicated enzyme-regulated process within 
follicles of the ovary, which begins with the conversion of cholesterol. Under the influence of 
LH, the thecal cell produces androgens that upon diffusion to the granulosa cell of the follicle 
are converted to estrogens through a FSH-supported aromatization reaction. This interaction 
between the thecal cell and granulosa cell compartments of the ovarian follicles, which is 
controlled by LH and FSH, helps explain how ovarian steroidogenesis is controlled. 
Estrogens 
Estrogens are predominant ovarian hormones that include 1713- estradiol (estradiol), 
estriol, and estrone. Both estrone and estradiol are present in the blood stream. Estradiol is 
secreted into the bloodstream directly by the ovary. Estrone derives largely from peripheral 
conversion of estradiol or androstenedione, where it is further metabolized to estriol in the 
liver. Most circulating estrogens ( ~80%) are bound to proteins. Approximately 60% of the 
estrogen transported in the bloodstream is bound to a steroid-binding protein called sex 
hormone-binding globulin (SHBG), otherwise known as testosterone-binding globulin 
(TeBG), for which estrogens have a higher affinity (16,26). The remaining estrogen not in 
free form (~20%) is bound to albumin, for which estrogens have a low affinity (16,26,30). 
However, in comparison with androgens, estrogens have a lower affinity for SHBG, which 
results in a greater availability of estrogens to the tissues because only free steroids are 
transported into their target cells. 
Estrogens are degraded in the liver to inactive metabolites, conjugated with sulfate or 
glucuronide, and excreted in the urine. Major metabolites of estradiol include estrone, 
estriol, and catecholestrogens ( 40). 
Testosterone 
Testosterone is a steroid hormone produced in the ovary and adrenal glands, while 
also being formed in peripheral tissues form androstenedione and to some extent from DHEA 
and ~5-androstenediol. Testosterone is formed from cholesterol, which can be synthesized de 
novo or derived from low-density lipoproteins (16,28,50), while the secretion of testosterone 
is regulated by the hypothalamus through the release of LH. Testosterone is the primary 
physiologically active androgen in women, which acts on target tissues directly or after it is 
converted to 5 a-dihydrotestosterone. Increased levels of testosterone are associated with 
increased strength and power ( 43,48). 
As in men, ~98% of the total circulating testosterone in women is bound to SHBG, 
thus leaving only 2% of the total plasma testosterone (free testosterone) available for 
metabolism (5,16,33). However, SHBG is found in higher concentrations in the plasma of 
women compared to men (44). As a result, the percentage of testosterone bound differs in 
women (96%) as opposed to men (93%). 
Excretion of testosterone and its metabolites occurs primarily in the urine. 
Androstenedione and etiocholanolone account for approximately 50% of the daily turnover 
of testosterone metabolites, while the other half is in the form of inactive polar metabolites 
( diols, triols, and conjugates) formed in peripheral tissue ( 16). Similar to estrogens, 
testosterone and its metabolites are excreted mostly in the urine. 
DHEA 
Dehydroepiandrosterone, and its major precursor DHEA-S, are hormonal precursors 
to testosterone, estrone, and estradiol. Dehydroepiandrosterone is converted in peripheral 
tissues to androstenedione, testosterone, and dehydrotestosterone (DHT) (2,6), and is also 
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aromatized to estrone and estradiol (30). Although the biosynthesis of DHEA and DHEA-S 
from cholesterol seem to be accomplished through pathways identical to those in male testis, 
there are gender differences in the production of such androgens in relation to testosterone 
formation. 
Gender Differences 
Dehydroepiandrosterone is converted in tissues to testosterone by a greater 
percentage in females compared to males (2,6,21). Haning et al. (18,19) suggested that 
circulating DHEA-S in females is taken up by the ovarian follicle and becomes an important 
source of testosterone within the follicle that is excreted into the blood. Therefore, DHEA-S 
serves as an important pre-hormone for circulating testosterone in women. Haning et. al. 
further suggested that DHEA-S is also an important precursor of ovarian testosterone after 
the administration of menotropins (17) and can be increased under the influence of FSH. 
Bird et al. (6) observed that women have a greater percentage of conversion of DHEA to 
testosterone than men, with reported values of 0.9% and 0.6%, respectively. Since 
androstenedione is converted to DHEA in a reaction catalyzed by 3 (3-hydroxysteroid 
dehydrogenase, androstenedione supplementation could theoretically increase DHEA levels 
that result in a greater amount of testosterone being converted in females. Therefore, 
androstenedione supplementation could increase testosterone in females to a higher 
concentration compared to males. 
Supplementation 
Ingestion of DHEA does not acutely affect testosterone concentrations in males (7). 
However, compared to males, female research suggests different results (36,37,38,46). 
Morales et al. (37) observed increases in serum testosterone and DHT in postmenopausal 
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women after 6 months of a 100-mg daily dose of DHEA supplementation. Supplementing 
half of the dosage (50-mg) of DHEA daily for six months, Morales et al. (36) observed two-
fold increases in serum testosterone and DHT in postmenopausal women. The majority of 
past research relating DHEA supplementation with testosterone concentrations has been done 
on postmenopausal women. It is unclear how premenopausal females would respond to 
DHEA supplementation as compared to postmenopausal females. Due to the differences in 
LH and FSH cycle patterns and enzymatic actitivities of converting androgens to estrogens, 
perhaps premenopausal may also benefit in testosterone concentrations following DHEA 
supplementation. Therefore, DHEA supplementation in premenopausal women demands 
further research. 
Although both DHEA and DHEA-S are aromatized to estrogens in non-pregnant 
women, the amount of estrogens formed is too small to be an important source of circulating 
estrogens in young women (19,31). Longcope et al. (29) observed an increase in the 
aromatization of DHEA to estrogens in postmenopausal women compared with college-aged 
women. Therefore, less aromatization of DHEA to estrogens in college-age women could 
provide the basis for greater conversion to testosterone and thus higher testosterone levels. 
Females have higher DHEA to testosterone conversion percentages than males. 
Premenopausal females aromatize less estrogen and thus allow more DHEA to be converted 
to androgens than postmenopausal females. Since DHEA and androstenedione are 
interconvertable, androstenedione supplementation could substantially increase testosterone 
concentrations especially in premenopausal females. 
Androstenedione 
Androstenedione is an important source of plasma testosterone in women. Both the 
stroma cells of the ovaries and the adrenal glands secrete androstenedione. The majority of 
androstenedione formed is converted by the aromatase enzyme to estrone in the liver, in a 
similar manner to which testosterone is aromatized to estradiol (16,33). However, some 
androstenedione is converted to testosterone through the action of the 17 ~-hydroxysteroid 
dehydrogenase enzyme before entering the blood plasma (5,33). 
Gender Differences 
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In contrast to testosterone, plasma androstenedione concentrations are higher in 
women than in men (20,22). A significant amount of testosterone in women is derived from 
blood androstenedione. Horton and Tait (22) observed that nearly 60% of plasma 
testosterone in women is derived from plasma androstenedione by peripheral conversion 
compared with less than 2% in males. The production rate or secretion of androstenedione 
was also found to be higher in women, 3.4 mg/day compared to the 1.4 mg/day in males (22). 
These authors (22) also observed that 6% of the orally administered androstenedione enters 
the general circulation as plasma androstenedione, while -2% enters the plasma as 
testosterone in women. 
Androstenedione appears to be the major androgen secreted in young adult females 
since it gives rise to most of the circulating plasma testosterone. The production of 
androstenedione rather than testosterone in women but not in men is a major difference in 
androgen synthesis between genders. The function of testosterone and DHT derived from 
other blood precursors is also different between genders. In men, nearly all plasma 
testosterone results from direct testicular secretion of testosterone. Ito and Horton (24) 
observed that of the 253 µg of DHT produced per day in men, 203 µg (59%) was derived 
14 
from testosterone and 50 µg (14%) from androstenedione. The production of DHT in women 
(41 µg/day) primarily reflects the conversion of 36 µg of androstenedione and 3 µg of 
testosterone into DHT, suggesting an absence of direct secretion of DHT (24,47). 
There are various differences between genders in regard to androstenedione. A major 
difference which may explain why females respond differently to androstenedione 
supplementation is that 60% of plasma testosterone is derived from plasma androstenedione 
in females, in contrast to only 2% of plasma testosterone in males. Other major differences 
with females compared to males include that androstenedione is a more important source of 
plasma testosterone, a greater proportion of testosterone is derived from androstenedione, 
and androstenedione is the major secreted androgen giving rise to most of the circulating 
plasma testosterone. 
Supplementation 
The acute effects of oral androstenedione administration on serum testosterone 
concentrations in men are not well established. Two recent studies concluded that serum 
testosterone concentrations in men increase after ingestion of androstenedione (13,27). 
Earnest et al. (13) reported that the incremental area under the curve for serum testosterone 
concentrations during 90 minutes following the ingestion of 200-mg androstenedione was 
higher compared with placebo. Following ingestion, however, total testosterone and free 
testosterone were not significantly higher at any time point. The authors reported the values 
for area under the curve by apparently including the area attributable to baseline serum 
testosterone concentrations, which were slightly higher in the androstenedione-supplemented 
group of subjects. 
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King et al. (25) were the first researchers to show that a 100-mg dose of oral 
androstenedione supplementation does not increase serum testosterone concentrations in 
young men. A single 100-mg dose given to ten normotestosterogenic men did not increase 
serum testosterone for up to six hours. The authors also observed a lack of enhancement in 
skeletal muscle adaptation to resistance training with androstenedione supplementation over 
an 8-week period, when given three 100-mg doses daily. 
In agreement with King et. al. (25), later research agreed with these findings 
(3,8,27,41,49). Leder et al. (27) observed no change in serum testosterone concentrations for 
8 h after subjects ingested 100-mg androstenedione, in agreement with previous acute 
response research with identical dosage (3,8,25,41,49). Leder et al. (27) also found no 
change in basal serum testosterone concentrations during one week of 100- or 300-mg single 
daily doses of androstenedione. However, the authors observed a mean increase in serum 
testosterone concentrations by ~34% during 8 h following a single 300-mg dose of 
androstenedione. These results suggest single doses of <300-mg of androstenedione do not 
increase serum testosterone in young men, while 300-mg produces a small and transient 
increase. 
The acute effects of androstenedione supplementation in women are unclear and are 
far less studied. The only research study testing the effect of androstenedione 
supplementation on serum testosterone concentrations in women observed substantial 
elevations in testosterone concentrations of two healthy women (32). In these women, 100-
mg of ingested androstenedione resulted in increases in serum androstenedione 
concentrations from O to 5 nmol/L and increases of total testosterone concentrations from 3 
16 
to 18 nmol/L. The authors failed to describe the two subjects in terms of age or reproductive 
status. 
Conclusion 
Some of the underlying mechanisms for possible differences in serum testosterone 
responses which have been mentioned previously include: 1) higher percentage conversion of 
DHEA to testosterone in women; 2) higher TeBG concentrations in women; 3) higher 
amounts of plasma testosterone derived from plasma androstenedione in women; 4) higher 
overall plasma androstenedione concentrations in women; and 5) higher secretion rate of 
androstenedione in women. Since only one poorly designed and executed study has been 
conducted on the effects of oral androstenedione ingestion in females, the extent to which 
oral androstenedione affects sex steroid concentrations in women should be determined. 
Subjects 
CHAPTER3 
1\1ETHODS 
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Eight healthy college-aged females were recruited for this experiment. Before 
participating in this study, subjects signed an informed consent form previously approved by 
the Iowa State University Human Subjects Review Committee. Subjects completed a self-
administered written medical history to eliminate any subjects with known metabolic 
disorders or abnormal menstrual cycles. All subjects were screened to ensure no oral 
contraceptive use. In addition, all subjects were screened regarding previous or current use 
of nutritional supplements and to ensure no current use of androstenedione. 
Design of Study 
On three separate occasions, separated by one month and after an overnight fast, a 
100-mg androstenedione, 300-mg androstenedione, or placebo (83-mg rice flour) was 
administered in a randomly assigned double-blind manner. Dietary intake was assessed for 
three days prior to testing, with this same dietary pattern replicated by each subject before 
each testing period. Blood samples were obtained before and every thirty minutes post 
ingestion up to 240 minutes (4 h). Serum hormone concentrations were determined as 
described below. 
Experimental Procedures · 
Subjects reported to the laboratory following a 10-12 hour overnight fast between 
0600 and 0900, during the follicular phase of the menstrual cycle (day 3-5 after 
mensturation). Prior to supplementation, a baseline blood sample (0 min) was taken. Before 
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each 10-ml blood sample was obtained for serum hormonal analysis, a 2-3 ml blood sample 
was obtained first to ensure a "clean" sample for analysis. Blood samples were drawn with a 
12-ml syringe from a flexible teflon catheter inserted into an antecubital vein. Blood was 
immediately transferred to a serum collection tube containing SST gel and clot activator. 
After clotting, the blood was placed on ice until centrifugation. After centrifugation the 
serum was pipetted off and frozen at -80° C until assayed for hormone assessment as 
described below. 
Diet Record 
Dietary intake was replicated for three days prior to each test day. Subjects recorded 
a 3-day diet record prior to the morning of trial 1, with a similar dietary pattern repeated for 
the remaining two trials. Subjects were queried frequently and reminded to ensure that they 
maintained a semi-controlled diet. A dietary analysis was run on each subject's diet 
(Nutritionist IV). 
Anthroprometric Data 
Height was measured prior to trial one and weight was measured prior to each trial 
using a Deteco™ (Webb City, MO, USA) upright wall stadiometer with .5 cm and .1 kg 
precision, respectively, to monitor weight fluctuations. Body composition was determined 
between trials 2 and 3 using hydrostatic weight. Eight trials of underwater weighing were 
performed per subject, while the lowest two identical body masses in water were used for 
body density calculation. Body density and body fat percentage were calculated using the 
techniques specified and Broyile formulas given by the American College of Sports 
Medicine (1). 
Hormonal Analyses 
Serum concentrations of androstenedione and total testosterone were measured with 
radioimmunoassay (RIA) using commercially available kits (Diagnostic Products, Los 
Angeles, CA). Serum concentrations of estradiol were measured with RIA using 
commercialy available kits (Diagnostic Systems Laboratories, Webster, TX). 
Statistical Analysis 
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Data were analyzed using commercial software (SPSS Inc, Chicago, Ill). A statistical 
analysis was performed using two-way (time and treatment) analyses of variance (ANOV A) 
with repeated measures. When ANOV A revealed a significant interaction (P<0.05), specific 
mean differences were located with a Newman-Keuls multiple-comparison test. 
Subjects 
CHAPTER4 
RESULTS 
Of the ten subjects who started this project, two subjects withdrew due to time 
conflicts and menstrual cycle problems. 
Subjects Age (y) Height (cm) Weight (kg) Body Fat(%) 
n=8 22.1 ± 0.4 165.0 ± 3.8 58.6 ± 4.2 20.3 ± 2.0 
Values are means ± SE. 
Table 1. Age and anthropometric data of the the subjects. 
Serum Androstenedione Response 
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The baseline serum androstenedione concentration (Figure 4) was not different in 
placebo (PLA), the 100-mg dose (LO), or the 300-mg dose (HI) prior to ingestion. Serum 
androstenedione concentrations increased 60 min after ingestion in both LO and ID and 
remained elevated compared with PLA during the 240 min after ingestion (p < 0.05). The 
serum androstenedione concentration was higher (p < 0.05) in ID compared with LO from 
120 to 240 min. At 240 min, serum androstenedione concentrations in LO (22.6 ± 1.0 
nmol/L) and HI (28.1 ± I.I nmol/L) were 317% and 410% higher, respectively, compared 
with PLA (5.5 ± 0.8 nmol/L). The area under the curve (AUC) for LO and HI (Figure 5) was 
higher than PLA (p < 0.05) and was higher in HI (3151.9 ± 380.0 nmol/L•min) compared 
with LO (2245.1 ± 346.5 nmol/L•min). 
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Figure 4. Serum androstenedione response to intake of placebo (PLA), 100-mg (LO), or 
300-mg (HI) androstenedione. 
* LO and HI significantly different from PLA, p < 0.05 
t HI significantly different from LO, p < 0.05 
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Figure 5. Area under the curve (AUC) of serum androstenedione response to intake of 
placebo (PLA), 100-mg (LO), or 300-mg (HI) androstenedione. 
* PLA significantly lower than LO and HI; t HI significantly higher than LO, p < 0.05 
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Serum Estradiol Response 
Serum concentrations of estradiol (Figure 6) were not different prior to 
androstenedione ingestion before 150 min in PLA, LO, or HI. Serum concentrations of 
estradiol was higher in LO compared with PLA at 150 min (p < 0.05). Serum concentrations 
of estradiol were higher at each time point throughout min 150 to240 in HI compared with 
PLA (p < 0.05). A 62% increase in serum estradiol concentration at 210 min was observed 
in HI above that of PLA. The estradiol serum concentration was not different in LO or HI at 
any time point. 
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Figure 6. Serum estradiol response to intake of placebo (PLA), 100-mg (LO), or 300-mg 
(HI) androstenedione. 
* LO significantly different from PLA, p < 0.05 
t HI significantly different from PLA, p < 0.05 
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Serum Total Testosterone Response 
Serum total testosterone concentration (Figure 7) was not different in PLA, LO, or ID 
at baseline through 60 min after ingestion. Serum total testosterone concentrations in HI and 
LO were higher (p < 0.05) compared with PLA at 60 min and 120 min, respectively, and 
remained higher through 240 min. At the 210 and 240 min point, serum total testosterone 
concentrations in both HI (10.2 ± 1.6 nmol/L) and LO (5.5 ± 0.9 nmol/L) were -627% and 
-293% higher, respectively, compared with PLA (1.4 ± 0.2). There was no difference in 
serum total testosterone concentration between LO and ID before 120 minutes. Serum total 
testosterone concentration was higher (p < 0.05) in HI compared with LO from 120-240 min, 
with an 85% higher serum total testosterone concentration in ID at 240 min after ingestion. 
The AUC was higher in HI (1343.3 ± 257.8 nmol/L•min) compared with LO (631.9 ± 94.2 
nmol/L•min; p < 0.05). 
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Figure 7. Serum total testosterone response to intake of placebo (PLA), 100-mg (LO), or 
300-mg (HI) androstenedione. 
* Significantly different from PLA; t HI significantly different from LO, p < 0.05 
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Figure 8. Area under the curve (AUC) of serum total testosterone concentration response to 
intake of placebo (PLA), 100-mg (LO), or 300-mg (HI) androstenedione. 
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t HI significantly different from LO, p < 0.05 
CHAPTERS 
DISCUSSION 
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A major finding of this study is that short-term androstenedione supplementation 
increased the serum total testosterone concentration in young women with normal serum 
testosterone levels. Furthermore, serum total testosterone was higher after ingestion of 300-
mg androstenedione compared to 100-mg. 
The only prior report on androstenedione administration in women (32) also 
demonstrated substantial elevations in the blood testosterone concentration in two healthy 
women, but to a greater extent than the increase seen in this present study. Mahesh and 
Greenblatt (32) showed that 100-mg of androstenedione increased blood total testosterone 
from 3 to 18 nmol/L (300%) 60 min after ingestion, with a plateau at 90 min. In the present 
study, 100-mg of androstenedione increased serum total testosterone concentration from 1.2 
to 5.5 nmol/L at 240 min after ingestion. Serum total testosterone concentration was only 
increased by 2 nmol/L from baseline after 60 min, in contrast to the 15 nmol/L increase at 60 
min after intake seen by Mahesh and Greenblatt (32) with a 100-mg dose. Ingestion of 300-
mg androstenedione in the present study led to only an 8 nmol/L increase in serum total 
testosterone concentration after 240 min. The prolonged serum testosterone response, along 
with the milder increase in serum testosterone seen in the present study, leads to speculation 
of possible but unknown differences between the Mahesh and Greenblatt (32) and the present 
study. 
The response of serum androstenedione concentration after ingestion in the present 
study contrasts with Mahesh and Greenblatt (32) and may help explain the lower increase in 
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serum total testosterone seen in this present study. Mahesh and Greenblatt (32) showed that 
100-mg of androstenedione increased the blood androstenedione concentration from Oto 5 
nmol/L at 60 min after ingestion. In the present study with 100-mg androstenedione, a 6 to 
11 nmol/L increase in serum androstenedione concentration after 60 min was seen with a 
continuing elevation to 23 nmol/L after 240 min. The higher serum androstenedione 
response observed in the present study, associated with a lower total testosterone response, 
may indicate less conversion to serum total testosterone through 17 f3-hydroxysteroid 
dehydrogenase. 
Age differences in the subjects between the present study and Mahesh and Greenblatt 
(32) may also explain the higher increase in testosterone concentration seen in Mahesh and 
Greenblatt (32). The unknown ages of the two subjects in Mahesh and Greenblatt, along 
with a 15 nmol/L higher blood total testosterone concentration at 60 min after ingestion, 
leads to speculation that the subjects were postmenopausal. Postmenopausal females with 
hypoestrogenic conditions may respond with a higher blood total testosterone concentration 
after androstenedione supplementation (38, 46). Despite not assaying for estrone or 
measuring the enzymatic kinetics of P450 Aromatase and 17 f3-hydroxysteroid 
dehydrogenase in the present study, it is the author's opinion that the lower aromatizing 
activity of androstenedione to estrogens through P450 aromatase in postmenopausal women 
compared to normoestrogenic premenopausal women may result in higher conversion rates 
of androstenedione to testosterone through the enzymatic activity of 17 f3-hydroxysteroid 
dehydrogenase. In addition, the possible use of postmenopausal subjects, along with an 
unknown hormonal status and day of menstrual cycle during the testing periods employed by 
Mahesh and Greenblatt (32), may result in contrasting conversion rates between androgens 
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and estrogens and thus possibly explain a gr~ater increase in total testosterone concentration 
compared with what we are reporting in the present study. 
The time period in which testosterone concentration returned to baseline levels after 
androstenedione ingestion is in contrast to findings from Mahesh and Greenblatt (32). The 
present study obtained blood samples for 240 min after ingestion, in contrast to 90 min by the 
Mahesh and Greenblatt (32) study. Previously, 100-mg of androstenedione administration in 
men has shown that blood androstenedione concentrations level off approximately 4 h after 
ingestion (25,27,41). A longer sustained elevation in blood androstenedione concentration 
seen in past research in males (25,27,41) and in this present study is in contrast to Mahesh 
and Greenblatt (32), demonstrating that blood androstenedione concentration plateaued at 60 
min and dropped at 90 min after intake. The reason for a shorter testosterone response 
observed by Mahesh and Greenblatt (32) compared to the more prolonged testosterone 
response seen in this present study and past research in men is unknown. 
The increased total testosterone concentration after androstenedione ingestion seen in 
this present study and previous research in females (32) is in contrast to previous research in 
males (3,8,25,27,41,49). For example, King et. al. (25) showed higher relative increases in 
estradiol compared to this present study, where 100-mg only increased estradiol at 150 min 
and 300-mg increased estradiol from 150-240 min. It may be possible that following the 
androstenedione ingestion in females, more of the ingested androstenedione remained as 
estrone rather than being converted further to estradiol. King et. al. (25) suggested that the 
unchanged serum testosterone concentration following androstenedione ingestion, in spite of 
the higher androstenedione concentration, is due to an increased formation of estrogens from 
the exogenous androstenedione. The smaller relative increase in estradiol seen in the present 
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study compared with research in males {3,8,25,27,41,49) suggests that a significant 
proportion of the ingested androstenedione was preferably converted to testosterone through 
the enzymatic activity of 17 f3-hydroxysteroid dehydrogenase, with less androstenedione 
undergoing aromatization to estrogens. A purported preferred conversion of ingested 
androstenedione to testosterone in females is reasonable since 6% of the orally administered 
androstenedione enters the general circulation as plasma androstenedione (22). In addition, 
nearly 60% of plasma testosterone is derived from plasma androstenedione by peripheral 
conversion (22). The 60% of plasma testosterone derived from androstenedione in females is 
far greater than the 2% of plasma testosterone derived from androstenedione in men (22). 
Therefore, less estrogen conversion from ingested androstenedione, along with a higher 
percent conversion of plasma testosterone from androstenedione, implicates a possibly higher 
testosterone response to androstenedione ingestion in women compared with men. 
Androstenedione is converted to DHEA in a reaction catalyzed by 3 f3-hydroxysteroid 
dehydrogenase, while DHEA is further converted to testosterone. The percentage ofDHEA 
conversion back to androstenedione and furthermore to testosterone in tissues is greater in 
females compared to males (2,6,21). Previous research on DHEA supplementation has 
shown an increase in testosterone concentration in females (36,37,38,46), while it is 
unchanged in males (7). In addition, circulating DHEA-S in females is a more important pre 
cursor for testosterone, since DHEA-S is taken up by the ovarian follicle (18,19). Therefore, 
a greater DHEA-S concentration coming from the conversion of androstenedione may result 
in a higher testosterone concentration in females compared with males. Although DHEA 
concentration was not measured in this study, it is possible that DHEA concentrations were 
increased from the ingested androstenedione and thus further contributed to the higher 
testosterone response seen in females (32) compared to males (3,8,25,27,41,49). 
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An increase in testosterone as a result of androstenedione supplementation may be 
desirable for amateur and professional female athletes. Testosterone stimulates muscle 
protein synthesis by activating a hormone receptor complex that increases mRNA and DNA 
synthesis (11,16,22). Therefore, a higher testosterone concentration may be beneficial for 
female athletes and competitors seeking an increase in muscle mass and muscular strength 
(11). In addition, androgen therapy is becoming more popular in not only postmenopausal 
females experiencing postmenopausal and glucocorticosteroid-related bone loss, but also 
premenopausal females who show androgen deficiency symptoms such as premature ovarian 
failure. 
Although their appear to be potential benefits to androstendione supplementation in 
fe·males, an increase in testosterone concentration may result in potentially serious adverse 
health consequences in young females. Above normal testosterone concentrations in females 
may be associated with hirsutism (34 ), especially when the testosterone/SHBG ratio 
increases (9). High testosterone concentrations in females also increase a number of the risk 
factors for atherosclerotic cardiovascular disease. A 9-fold increase in serum testosterone 
has been observed to increase the integrated insulin concentration without a change in fasting 
glucose insulin values (38). This adverse affect on insulin sensitivity due to increased 
testosterone concentrations may contribute to diabetes and/or an increased risk of renal injury 
( 42). In addition, a drop in HDL-cholesterol values is associated with increased testosterone 
concentrations in both males and females (4,10,35,38). For example, Bamkart et. al. (4) 
showed a 10% decrease in HDL-cholesterol concentrations accompanied by a 95% increase 
in testosterone concentration. Finally, an increase in hypertension (42) and impaired flow-
mediated dilation and vascular reactivity (35) have been associated with above normal 
increased testosterone concentrations in females. 
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In summary, acute administration of 100- and 300-mg androstenedione significantly 
increased the blood total testosterone concentration in healthy college-aged women, but 
significantly less than the only research previously conducted in female subjects. However, 
the ability to increase serum testosterone concentrations following orally ingested 
androstenedione is in contrast with research in males showing no effect. A lower estrogen 
response, along with gender differences in the conversion rates of androstenedione in 
forming testosterone, provides a possible explanation for a different testosterone response 
between genders. Although an increase in testosterone may be desirable in some populations 
(i.e., pre- and postmenopausal females with androgen deficiency symptoms), the potential 
health consequences and benefits from increased testosterone concentrations should be 
considered when conducting further research in females using androstenedione 
supplementation. 
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